Navigation Links
Daiichi Sankyo and Charleston Laboratories Announce Collaboration to Develop and Commercialize Novel, Fixed-Dose Combination Hydrocodone Products for Pain and Opioid-Induced Nausea and Vomiting (OINV) in the US
Date:8/6/2014

108 and will receive the right to co-promote this and other hydrocodone products in the United States.

Under the terms of the agreement, which is pending Hart-Scott-Rodino clearance, Charleston Laboratories will receive $200 million, split evenly between an upfront cash payment and a near-term milestone and up to an additional $450 million in milestone payments connected to the filing and approval of its novel fixed-dose hydrocodone products in the United States.  In addition, Charleston Laboratories will receive an escalating, tiered, double-digit share of the gross operating margin from the products.  

"We are proud to partner with Charleston Labs on this exciting and unique fixed-dose combination tablet, which will seek to simultaneously address severe pain and opioid-related nausea and vomiting to benefit patients," said Dr. Mahmoud Ghazzi, MD, PhD, Global Head of Development and Executive Vice President at Daiichi Sankyo Co., Ltd.

"CL-108 represents an opportunity at the intersection of innovation and patient need," said Ken Keller, President, U.S. Commercial of Daiichi Sankyo, Inc. "Daiichi Sankyo has proven success in the U.S. primary care arena, a key market for pain management, and we look forward to the potential of CL-108."

"From our inception, it has been our goal to identify an industry-leading partner that is patient-focused, with a shared appreciation for the importance of educating healthcare providers on the significant issue of Opioid-Induced Nausea and Vomiting," said Ryan Baker, Founder and Chief Operating Officer of Charleston Laboratories. "Daiichi Sankyo has successfully commercialized several medicines in the United States, and we feel they are the ideal strategic fit for Charleston's lead asset, CL-108."

"Charleston is e
'/>"/>

SOURCE Daiichi Sankyo, Inc.
Copyright©2014 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Daiichi Sankyo, Virtici and Celdara Medical Announce Collaboration to Identify and Progress High Potential Therapeutics
2. Daiichi Sankyo Submits Edoxaban Marketing Authorization Application to the EMA for Once-Daily Use for Stroke Prevention in Atrial Fibrillation and for the Treatment and Prevention of Recurrence of Venous Thromboembolism
3. Daiichi Sankyos Once-Daily Edoxaban Meets Primary Efficacy Endpoint for Stroke Prevention and Superiority for the Principal Safety Endpoint Compared to Warfarin for Patients with Atrial Fibrillation in a Phase 3 Clinical Trial
4. Daiichi Sankyos Once-Daily Edoxaban Shows Comparable Efficacy and Superiority for the Principal Safety Endpoint Compared to Warfarin in a Phase 3 Study for the Treatment of Symptomatic VTE and Prevention of its Recurrence
5. Daiichi Sankyo CEO John Gargiulo Elected as National Pharmaceutical Councils Chairman of the Board
6. Daiichi Sankyo ha completato larruolamento dei pazienti per lo studio Hokusai-VTE su Edoxaban, il piĆ¹ ampio trial clinico di fase 3 per il trattamento delle tromboembolie venose ricorrenti
7. Daiichi Sankyo Completes Enrolment in Hokusai - VTE, investigating once-daily Edoxaban in the Largest Single Phase 3 Study for the Treatment and Prevention of Recurrence of VTE
8. Daiichi Sankyo, Inc. Receives FDA Approval to Package Product at New Facility in Bethlehem, PA
9. CHPA Addresses Anti-Meth Policy at AP Lookahead Event Today in Charleston
10. CHPA to Address Anti-Meth Policy at AP Lookahead Event Today in Charleston
11. Strong Efficacy Data Prompt Charleston Laboratories to Halt Phase 3 Study of CL-108 in Patients with Moderate to Severe Acute Pain
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/17/2015)... Sigma-Aldrich Corporation (NASDAQ: ... Technology company, today announced the opening of its ... state-of-the-art Cell Culture Technical Center in Singapore.  Located ... customized support to meet customer needs, leveraging the ... new Technical Center will significantly enhance our ability ...
(Date:4/17/2015)... , April 17, 2015 TWi Pharmaceuticals, ... subsidiary, TWi Pharmaceuticals USA , has ... the United States.  It has been in close contact ... and expects to have its own label specialty generic ... in the U.S. pharma market. According to ...
(Date:4/16/2015)... , April 16, 2015 Mindray ... developer, manufacturer, and marketer of medical devices worldwide, ... Securities and Exchange Commission an Annual Report on Form ... year ended December 31, 2014. An electronic version of ... on Mindray,s investor relations website at  http://ir.mindray.com  or  ...
Breaking Medicine Technology:Sigma-Aldrich Expands Customer-Centric Model with Investments in Singapore That Localize World-Class Capabilities to Better Support Customers in Asia 2Sigma-Aldrich Expands Customer-Centric Model with Investments in Singapore That Localize World-Class Capabilities to Better Support Customers in Asia 3Sigma-Aldrich Expands Customer-Centric Model with Investments in Singapore That Localize World-Class Capabilities to Better Support Customers in Asia 4Sigma-Aldrich Expands Customer-Centric Model with Investments in Singapore That Localize World-Class Capabilities to Better Support Customers in Asia 5Mindray Files Annual Report on Form 20-F with the U.S. Securities and Exchange Commission 2
... 14, 2011 Reportlinker.com announces that a new ... Test-Volume-Sales-Forecasts-and-Supplier-Shares-by-Country.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=In_Vitro_Diagnostic title=,The 2011 Prostatic ... Test Volume, Sales ... Acid Phosphatase Testing Market: US, Europe, Japan ...
... Nov. 14, 2011 Reportlinker.com announces that a ... catalogue: Smart Infusion Pumps ... is one of the most common therapeutic procedures ... to receive. Yet the lack of standardization among ...
Cached Medicine Technology:The 2011 Prostatic Acid Phosphatase Testing Market: US, Europe, Japan 2The 2011 Prostatic Acid Phosphatase Testing Market: US, Europe, Japan 3The 2011 Prostatic Acid Phosphatase Testing Market: US, Europe, Japan 4The 2011 Prostatic Acid Phosphatase Testing Market: US, Europe, Japan 5Smart Infusion Pumps 2Smart Infusion Pumps 3
(Date:4/18/2015)... has released a new blog post explaining how to ... fire damage. , Clients can now find auto insurance ... set intentionally on fire. This type of damages can be ... , It is possible to compare the best online ... , in just a few minutes. Clients should always review ...
(Date:4/18/2015)... Insuranceautoquote.info has released a new blog ... quotes . , Clients can review important auto ... online environment provides important advantages for clients who need ... who do not have coverage for their vehicles can ... day or hour. Many agencies offer important discounts and ...
(Date:4/18/2015)... (PRWEB) April 18, 2015 Thousand of ... on behalf of individuals who were allegedly harmed by ... to move forward in the U.S. District Court, Northern ... 10th, the Court has amended an earlier Case Management ... Among other things, the new amendment permits the claims ...
(Date:4/18/2015)... NE (PRWEB) April 18, 2015 ... in healthcare staffing, including physical therapy jobs, has ... at the South Carolina Physical Therapy Association Annual ... the Kroc Center in Greenville, SC. , ... opportunities, and exhibits with products and services. ...
(Date:4/17/2015)... 18, 2015 Heritage Woods of McLeansboro, ... Supportive Living Week Celebration on April 20 with a ... healthy mind, body and soul. , The community, which ... serves older adults of all incomes, including those on ... , Supportive Living Week is observed every April and ...
Breaking Medicine News(10 mins):Health News:Online Auto Insurance Quotes For Plans That Cover Fire Damages! 2Health News:Clients Can Review Car Insurance Quotes Online To Find Low Cost Offers! 2Health News:DePuy Pinnacle Hip Lawsuits: Federal Litigation Amends Case Management Order to Allow for Joinder of Unrelated Claims 2Health News:DePuy Pinnacle Hip Lawsuits: Federal Litigation Amends Case Management Order to Allow for Joinder of Unrelated Claims 3Health News:Healthcare Staffing Leader, Aureus Medical Group, to Exhibit at the South Carolina Physical Therapy Association Annual Conference 2Health News:Heritage Woods of McLeansboro Affordable Assisted Living to Celebrate Supportive Living Week 2Health News:Heritage Woods of McLeansboro Affordable Assisted Living to Celebrate Supportive Living Week 3
... regimen popular in 1980s doesn,t really lengthen life , , ... only a minimal effect on survival in breast cancer ... pretty clearly established that [high-dose chemotherapy] is a false ... Division of Quantitative Sciences at the University of Texas ...
... is a three-day multidisciplinary meeting that will serve as ... the prevention, screening and treatment of gastrointestinal cancers. More ... years Symposium which will feature nearly 600 scientific abstracts. ... 27, 2008, WHERE:, Orlando World Center Marriott , 8701 ...
... at the Universities of Nottingham and Leicester are collaborating ... image and quantify the air spaces inside the lungs ... to a link between childhood disease and later degenerative ... the world which have access to this particular magnetic ...
... Boston, MAMichael F. Holick, PhD, MD, was recently awarded ... Society of Endocrinology and Metabolism (CSEM). Holick, an ... received the award for decades of pioneering work that ... wide variety of chronic health conditions. , ...
... at Henry Ford Hospital on the use of a drug ... and aggressive type of brain cancer, has yielded results that ... II study focused on patients with glioblastoma multiforme (GBM), whose ... revealed that more than a third who were treated with ...
... them from being attacked by the female immune system could ... the human body, according to new research published on 14 ... in the Journal of Biological Chemistry, analysed these markers which ... sperm are not dangerous pathogens, and therefore should not be ...
Cached Medicine News:Health News:High-Dose Chemo Provides Little Benefit to Breast Cancer Patients 2Health News:High-Dose Chemo Provides Little Benefit to Breast Cancer Patients 3Health News:New technique reveals insights into lung disease 2Health News:Boston University Medical Center researcher honored 2Health News:Drug study for brain cancer shows promising results 2Health News:Sperm's immune-protection properties could provide link to how cancers spread 2
... Modes of Operation: , Double Burst : 2 60-ms ... Twitch: 1 s (1 pulse/s) , Tetanus: 50 ... , Train-Of-Four: Single (4 pulses/2 s) , Output Current: ... Wave Monophasic pulses (200-us duration) , Indicators: Battery LED ...
Anesthesia Associates Nerve Stimulator Model AA 1050...
... The Stimuplex HNS11 is the newest peripheral nerve ... latest generation of Stimuplex stimulators providing advanced digital ... pulse duration of the HNS11 allows the localization ... peripheral nerve blocks. , ,An additional optional ...
... original MS-III design the new ... keypad and battery ... MS-IV peripheral nerve stimulator can ... in operating room, post anesthesia ...
Medicine Products: